Journal Article
. 2016 Mar;141(2).
doi: 10.1016/j.ygyno.2016.03.006.

Estrogen receptor-alpha as a predictive biomarker in endometrioid endometrial cancer

Floor J Backes 1 Christopher J Walker 2 Paul J Goodfellow 2 Erinn M Hade 3 Garima Agarwal 2 David Mutch 4 David E Cohn 2 Adrian A Suarez 5 
  • PMID: 26957478
  •     29 References
  •     21 citations


Background: We sought to validate the prognostic significance of estrogen receptor alpha (ERα) expression and to investigate the relationship between ESR1 mutation status and outcomes in a large cohort of patients with endometrial cancer. We also investigated the predictive value of ERα for lymph node involvement in a large surgically staged cohort.

Methods: A tumor microarray (TMA) was constructed including only pure endometrioid adenocarcinomas, stained with ER50 monoclonal antibody, and assessed using digital image analysis. For mutation analysis, somatic DNA was extracted and sequenced for ESR1 gene hotspot regions. Differences in patient and tumor characteristics, recurrence and survival between ERα positive and negative, mutated and wild-type tumors were evaluated.

Results: Sixty (18.6%) tumors were negative for ERα. Absence of ERα was significantly associated with stage and grade, but not with disease-free or overall survival. ERα was a strong predictor of lymph node involvement (RR: 2.37, 95% CI: 1.12-5.02). Nineteen of 1034 tumors (1.8%) had an ESR1 hotspot mutation; twelve in hotspot 537Y, four in 538D and three in 536L. Patients with an ESR1 mutation had a significantly lower BMI, but were comparable in age, stage and grade, and progression-free survival.

Conclusion: Patients with ERα negative endometrioid endometrial cancer are more often diagnosed with higher grade and advanced stage disease. Lymph node involvement is more common with lack of ERα expression, and may be able to help triage which patients should undergo lymphadenectomy. Mutations in ESR1 might explain why some low risk women with low BMI develop endometrial cancer.

Keywords: Biomarker; ESR1; Endometrial cancer; Estrogen receptor alpha; Lymph node metastasis; Survival.

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study.
ASTEC study group, H Kitchener, +3 authors, M K B Parmar.
Lancet, 2008 Dec 17; 373(9658). PMID: 19070889    Free PMC article.
Highly Cited.
Systematic pelvic lymphadenectomy vs. no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial.
Pierluigi Benedetti Panici, Stefano Basile, +23 authors, Costantino Mangioni.
J Natl Cancer Inst, 2008 Nov 27; 100(23). PMID: 19033573
Highly Cited.
Current issues in ER and HER2 testing by IHC in breast cancer.
Allen M Gown.
Mod Pathol, 2008 Jun 24; 21 Suppl 2. PMID: 18437174
High frequency strand slippage mutations in CTCF in MSI-positive endometrial cancers.
Israel Zighelboim, David G Mutch, +4 authors, Paul J Goodfellow.
Hum Mutat, 2013 Oct 17; 35(1). PMID: 24130125    Free PMC article.
Detection of sentinel lymph nodes in patients with endometrial cancer undergoing robotic-assisted staging: a comparison of colorimetric and fluorescence imaging.
Robert W Holloway, Ricardo A Molero Bravo, +4 authors, Sarfraz Ahmad.
Gynecol Oncol, 2012 Apr 18; 126(1). PMID: 22507531
Patterns of CTCF and ZFHX3 Mutation and Associated Outcomes in Endometrial Cancer.
Christopher J Walker, Mario A Miranda, +6 authors, Paul J Goodfellow.
J Natl Cancer Inst, 2015 Sep 04; 107(11). PMID: 26330387    Free PMC article.
ESR1 ligand-binding domain mutations in hormone-resistant breast cancer.
Weiyi Toy, Yang Shen, +15 authors, Sarat Chandarlapaty.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185512    Free PMC article.
Highly Cited.
Gene expression profiling predicts clinical outcome of breast cancer.
Laura J van 't Veer, Hongyue Dai, +13 authors, Stephen H Friend.
Nature, 2002 Feb 02; 415(6871). PMID: 11823860
Highly Cited.
Prospective evaluation of DNA mismatch repair protein expression in primary endometrial cancer.
Floor J Backes, Marino E Leon, +7 authors, David E Cohn.
Gynecol Oncol, 2009 Jun 12; 114(3). PMID: 19515405
A modified poisson regression approach to prospective studies with binary data.
Guangyong Zou.
Am J Epidemiol, 2004 Mar 23; 159(7). PMID: 15033648
Highly Cited.
Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type.
Israel Zighelboim, Paul J Goodfellow, +4 authors, David G Mutch.
J Clin Oncol, 2007 May 22; 25(15). PMID: 17513808
Tumor heterogeneity at protein level as an independent prognostic factor in endometrial cancer.
Anna Supernat, Sylwia Lapińska-Szumczyk, +4 authors, Anna J Zaczek.
Transl Oncol, 2014 Jul 23; 7(5). PMID: 25048628    Free PMC article.
Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer.
Michael Frumovitz, Brian M Slomovitz, +5 authors, Diane C Bodurka.
J Am Coll Surg, 2004 Aug 25; 199(3). PMID: 15325608
A prospective blinded evaluation of the accuracy of frozen section for the surgical management of endometrial cancer.
Ashley S Case, Rodney P Rocconi, +4 authors, Warner K Huh.
Obstet Gynecol, 2006 Dec 02; 108(6). PMID: 17138769
Validation of 2-mm tissue microarray technology in gastric cancer. Agreement of 2-mm TMAs and full sections for Glut-1 and Hif-1 alpha.
Felix Berlth, Stefan P Mönig, +7 authors, Hakan Alakus.
Anticancer Res, 2014 Jul 02; 34(7). PMID: 24982335
Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Vincent Jongen, Justine Briët, +5 authors, Harry Hollema.
Gynecol Oncol, 2008 Dec 26; 112(3). PMID: 19108875
Cancer statistics, 2012.
Rebecca Siegel, Deepa Naishadham, Ahmedin Jemal.
CA Cancer J Clin, 2012 Jan 13; 62(1). PMID: 22237781
Highly Cited.
Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.
Caroline C Billingsley, David E Cohn, +3 authors, Paul J Goodfellow.
Cancer, 2014 Sep 17; 121(3). PMID: 25224212    Free PMC article.
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.
Soonmyung Paik, Gong Tang, +11 authors, Norman Wolmark.
J Clin Oncol, 2006 May 25; 24(23). PMID: 16720680
Highly Cited.
Population-based validation of the prognostic model ADJUVANT! for early breast cancer.
Ivo A Olivotto, Chris D Bajdik, +6 authors, Karen A Gelmon.
J Clin Oncol, 2005 Apr 20; 23(12). PMID: 15837986
Highly Cited.
Lack of estrogen receptor-α is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma.
Elisabeth Wik, Maria B Ræder, +11 authors, Helga B Salvesen.
Clin Cancer Res, 2013 Jan 16; 19(5). PMID: 23319822
The role of frozen section in surgical staging of low risk endometrial cancer.
Sanjeev Kumar, Sudeshna Bandyopadhyay, +5 authors, Rouba Ali-Fehmi.
PLoS One, 2011 Sep 14; 6(9). PMID: 21912633    Free PMC article.
Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Dan R Robinson, Yi-Mi Wu, +22 authors, Arul M Chinnaiyan.
Nat Genet, 2013 Nov 05; 45(12). PMID: 24185510    Free PMC article.
Highly Cited.
GATA3 expression in estrogen receptor alpha-negative endometrial carcinomas identifies aggressive tumors with high proliferation and poor patient survival.
Ingeborg B Engelsen, Ingunn M Stefansson, Lars A Akslen, Helga B Salvesen.
Am J Obstet Gynecol, 2008 Jul 05; 199(5). PMID: 18599012
Sampling strategies for tissue microarrays to evaluate biomarkers in ovarian cancer.
Jenny Permuth-Wey, David Boulware, +10 authors, Tuya Pal.
Cancer Epidemiol Biomarkers Prev, 2009 Jan 07; 18(1). PMID: 19124477    Free PMC article.
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.
Kathy S Albain, William E Barlow, +20 authors, Breast Cancer Intergroup of North America.
Lancet Oncol, 2009 Dec 17; 11(1). PMID: 20005174    Free PMC article.
Highly Cited.
Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer.
S C Dowdy, B J Borah, +6 authors, K C Podratz.
Gynecol Oncol, 2012 Jul 10; 127(1). PMID: 22771890
Frozen section underestimates the need for surgical staging in endometrial cancer patients.
Andrea Papadia, Guglielmo Azioni, +6 authors, Nicola Ragni.
Int J Gynecol Cancer, 2009 Dec 04; 19(9). PMID: 19955939
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, +29 authors, Antonio C Wolff.
J Clin Oncol, 2010 Apr 21; 28(16). PMID: 20404251    Free PMC article.
Highly Cited. Systematic Review.
Prognostic role of NF-YA splicing isoforms and Lamin A status in low grade endometrial cancer.
Lucia Cicchillitti, Giacomo Corrado, +6 authors, Enrico Vizza.
Oncotarget, 2016 Dec 16; 8(5). PMID: 27974701    Free PMC article.
Differential Impacts of Alternative Splicing Networks on Apoptosis.
Jung-Chun Lin, Mei-Fen Tsao, Ying-Ju Lin.
Int J Mol Sci, 2016 Dec 17; 17(12). PMID: 27983653    Free PMC article.
Mutation status coupled with RNA-sequencing data can efficiently identify important non-significantly mutated genes serving as diagnostic biomarkers of endometrial cancer.
Keqin Liu, Li He, +5 authors, Menglong Li.
BMC Bioinformatics, 2018 Jan 04; 18(Suppl 14). PMID: 29297280    Free PMC article.
Clinical and Genomic Crosstalk between Glucocorticoid Receptor and Estrogen Receptor α In Endometrial Cancer.
Jeffery M Vahrenkamp, Chieh-Hsiang Yang, +8 authors, Jason Gertz.
Cell Rep, 2018 Mar 15; 22(11). PMID: 29539426    Free PMC article.
Non-Coding RNAs in Endometrial Physiopathology.
Alessandro La Ferlita, Rosalia Battaglia, +4 authors, Cinzia Di Pietro.
Int J Mol Sci, 2018 Jul 25; 19(7). PMID: 30037059    Free PMC article.
Targeted Next-Generation Sequencing Identifies Actionable Targets in Estrogen Receptor Positive and Estrogen Receptor Negative Endometriod Endometrial Cancer.
Siti Syazani Suhaimi, Nurul-Syakima Ab Mutalib, +5 authors, Rahman Jamal.
Front Pharmacol, 2018 Jul 31; 9. PMID: 30057548    Free PMC article.
Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.
Robert Neff, Craig M Rush, +3 authors, Paul J Goodfellow.
Int J Cancer, 2018 Aug 10; 143(11). PMID: 30091462    Free PMC article.
Mechanisms for estrogen receptor expression in human cancer.
Hui Hua, Hongying Zhang, Qingbin Kong, Yangfu Jiang.
Exp Hematol Oncol, 2018 Sep 27; 7. PMID: 30250760    Free PMC article.
Crosstalk between SOX2 and cytokine signaling in endometrial carcinoma.
Chang-Jung Lee, Pi-Lin Sung, +7 authors, Yu-Ting Chou.
Sci Rep, 2018 Dec 05; 8(1). PMID: 30510261    Free PMC article.
Crosstalk of estrogen receptors and Wnt/β-catenin signaling in endometrial cancer.
Mariz Kasoha, Chrisoula Dernektsi, +5 authors, Ingolf Juhasz-Böss.
J Cancer Res Clin Oncol, 2019 Dec 23; 146(2). PMID: 31865530
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.
Genovefa Polychronidou, Vassiliki Kotoula, +14 authors, George Fountzilas.
PLoS One, 2018 Dec 07; 13(12). PMID: 30521558    Free PMC article.
Estrogen Signaling in Endometrial Cancer: a Key Oncogenic Pathway with Several Open Questions.
Adriana C Rodriguez, Zannel Blanchard, Kathryn A Maurer, Jason Gertz.
Horm Cancer, 2019 Feb 04; 10(2-3). PMID: 30712080    Free PMC article.
Highly Cited. Review.
Estrogen-independent molecular actions of mutant estrogen receptor 1 in endometrial cancer.
Zannel Blanchard, Jeffery M Vahrenkamp, +2 authors, Jason Gertz.
Genome Res, 2019 Aug 01; 29(9). PMID: 31362937    Free PMC article.
ETV4 Is Necessary for Estrogen Signaling and Growth in Endometrial Cancer Cells.
Adriana C Rodriguez, Jeffery M Vahrenkamp, +8 authors, Jason Gertz.
Cancer Res, 2020 Feb 13; 80(6). PMID: 32046982    Free PMC article.
A Possible Link of Genetic Variations in ER/IGF1R Pathway and Risk of Melanoma.
Tze-An Yuan, Vandy Yourk, +4 authors, Feng Liu-Smith.
Int J Mol Sci, 2020 Mar 11; 21(5). PMID: 32150843    Free PMC article.
Oestrogen receptor pathway activity is associated with outcome in endometrial cancer.
Willem Jan van Weelden, Louis J M van der Putten, +7 authors, Johanna M A Pijnenborg.
Br J Cancer, 2020 Jun 09; 123(5). PMID: 32507853    Free PMC article.
De Novo ESR1 Hotspot Mutation in a Patient With Endometrial Cancer Treated With an Aromatase Inhibitor.
Adeline Morel, Julien Masliah-Planchon, +7 authors, Maud Kamal.
JCO Precis Oncol, 2019 May 21; 3. PMID: 32914015    Free PMC article.
Identification of a novel subgroup of endometrial cancer patients with loss of thyroid hormone receptor beta expression and improved survival.
Daniel G Piqué, John M Greally, Jessica C Mar.
BMC Cancer, 2020 Sep 08; 20(1). PMID: 32894083    Free PMC article.
Potential Role for a Panel of Immunohistochemical Markers in the Management of Endometrial Carcinoma.
Amany Salama, Mohammad Arafa, +8 authors, El-Said M Abdel-Hady.
J Pathol Transl Med, 2019 Mar 01; 53(3). PMID: 30813708    Free PMC article.
Estrogen receptor 1 mutations in 260 cervical cancer samples from Chinese patients.
Xin-Min Yang, Zhi-Min Wu, +6 authors, Ou-Ping Huang.
Oncol Lett, 2019 Aug 28; 18(3). PMID: 31452755    Free PMC article.
Researches on the Correlation Between Estrogen and Progesterone Receptors Expression and Disease-Free Survival of Endometrial Cancer.
Siling Ren, Jingxian Wu, +4 authors, Xiaoling Mu.
Cancer Manag Res, 2020 Dec 19; 12. PMID: 33335423    Free PMC article.